| Annual · values | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | 0.00 | 0.12 | 0.05 | 0.03 | 0.00 | — |
| ROE | -1104.04% | -357.84% | -132.13% | -39.18% | -65.49% | — |
| ROA | -375.69% | -220.44% | -106.24% | -33.40% | -26.30% | — |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Book Value / Share | 1.44 | 10.54 | 2.27 | 5.84 | 4.83 | — |
Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in cancer treatment. It leverages expertise in oncology to advance antibody-drug conjugates, small molecule drug conjugates, a CDK9 inhibitor, and the VersAptx bioconjugation platform for next-generation targeted therapies. The company engages in research, development, manufacturing, commercialization, sublicensing, and distribution of its clinical-stage and preclinical programs within the biotechnology sector. Currently, Vincerx Pharma Inc. is pursuing a Plan of Liquidation and Dissolution, with its board unanimously recommending stockholder approval to enable potential distributions from remaining assets while winding down operations. This process includes evaluating strategic alternatives such as out-licensing and asset sales. Headquartered in Palo Alto, California, and founded in 2018, Vincerx Pharma Inc. operates in the United States, contributing to the oncology pipeline through its specialized drug development efforts.